The 24th European Academy of Dermatology and Venereology was held in Copenhagen, Denmark, from 7-11 October 2015. It has become Europe's biggest meeting of its kind with roughly 10,000 participants, approximately 3000 abstracts and about 180 exhibitors from all over the world. The organizers offer a venue for the latest cutting edge research and newest developments. Thus, their goal is to foster progress in clinical care and promote scientific excellence related to dermatovenereology for the benefit of patients with skin diseases.
The aim of this study was to evaluate the accuracy of preoperative diagnosis of skin tumours in a dermatological setting. Patients undergoing skin surgery at the Department of Dermatology without preoperative biopsy were prospectively enrolled. Preoperatively, a single clinical diagnosis was registered. The histopathological diagnosis, performed after excision, was registered as the correct diagnosis. The sensitivity and positive predictive value of the clinical diagnosis were calculated. A total of 2,953 tumours were included. Altogether, 55.1% of the excised lesions were malignant. Excision margins for malignant tumours were free from tumour cells in 96.0% of cases. The sensitivity for diagnosis of malignant tumour was 98.0% and the positive predictive value was 85.3%. In line with previous studies, the sensitivity and positive predictive value were highest for basal cell carcinoma, 95.4% and 85.9%, respectively. For squamous cell carcinoma, the corresponding values were 68.0% and 67.3%, and for melanoma, 70.6% and 51.3%.
The incidence of actinic keratosis (AK) is increasing, and several treatment options are available. The aim of this study was to describe clinical characteristics and treatment patterns in patients with AK treated by Danish dermatologists.
A multicenter, non-interventional, cross-sectional study was conducted. Three dermatology hospital departments and seven private dermatology clinics enrolled eligible AK patients consecutively during one week.
A total of 312 patients were included. Non-melanoma skin cancer (NMSC) was previously reported in 51.0% of patients and currently suspected in 9.4% of AK-affected anatomical regions. Lesions of AK were located primarily on the face (38.6%), scalp (12.8%), and hands (11.2%). Actinic keratosis commonly presented with multiple AK lesions (38.6%) and field cancerization (38.5%). The treatments used most frequently were cryotherapy (57.7%) and photodynamic therapy (PDT) with methyl aminolevulinate (17.1%) and imiquimod (11.2%). The likelihood of receiving cryotherapy was higher for men (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.10-2.47) and increased with age (2.2% per year, 0.4-4.0%). PDT represented the most frequently applied treatment for severe actinic damage and was more likely to be prescribed to women (OR 4.08, 95% CI 2.22-7.47) and young patients (OR 0.97 per year, 95% CI 0.95-0.99). The prevalence of severe actinic damage (17.3% versus 9.6%) and intake of immunosuppressive medication (29.0 versus 2.0) were higher among hospital patients compared with those treated in private practices (P
Psoriasis substantially impairs the health-related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures.
To assess the impact of adalimumab on patient-reported outcomes (PROs) of patients with moderate to severe psoriasis.
In a Phase II, randomized, controlled trial, the efficacy and safety of two dosages of adalimumab (40 mg weekly or every other week) versus placebo were assessed for 12 weeks in the treatment of moderate to severe plaque psoriasis. Patients completed the Dermatology Life Quality Index (DLQI), Short-Form 36 (SF-36) Health Survey, and EuroQOL-5D (EQ-5D) at baseline and 12 weeks. The primary endpoint was the percentage of patients achieving a > or =75% reduction in the Psoriasis Area and Severity Index score (PASI 75). Investigators assessed PASI and Physician's Global Assessment (PGA) scores.
Adalimumab patients (either dosage) displayed significantly greater improvements versus placebo patients in DLQI, EQ-5D, and SF-36 Mental Component Summary scores, as well as in Bodily Pain, Vitality, Social Functioning, Role-Emotional, and Mental Health domains. The adalimumab 40-mg weekly group also reported significantly greater improvements in SF-36 Physical Component Summary scores versus the placebo group.
Both adalimumab dosages were efficacious in improving dermatology-specific and general PROs in patients with moderate to severe psoriasis.